How NR Works: The Complete Guide to Nicotinamide Riboside Biology

What nicotinamide riboside really is

Nicotinamide riboside, almost always shortened to NR, is a naturally occurring form of vitamin B3. You take in trace amounts of it every day from cow’s milk, yeast, and certain meats.

What turned NR from a footnote in nutrition textbooks into a billion-ringgit supplement category was a 2004 paper from Charles Brenner’s laboratory, then at Dartmouth, which identified the NRK1 and NRK2 enzymes - kinases that phosphorylate NR into NMN inside human cells. That single discovery established a new entry route into the NAD+ salvage pathway, one that bypassed the bottleneck enzyme NAMPT entirely.

For Malaysian readers trying to make sense of the NAD+ supplement aisle at Watsons or Guardian, this matters because NR is not interchangeable with NMN even though both end up as NAD+. They take different roads into the cell, and those different roads have generated different clinical evidence, different regulatory standings, and different price points.

This guide walks through how NR actually works at the molecular level, what the human trials show, and what a serious buyer in Kuala Lumpur or Johor Bahru should weigh in 2026.

The NRK1 and NRK2 pathway, explained without the slides

Once you swallow an NR capsule, the molecule is absorbed in the small intestine and enters the bloodstream more or less intact. From there it reaches tissues - liver, muscle, kidney, brain - and crosses cell membranes through equilibrative nucleoside transporters.

Inside the cell, the NRK1 enzyme, found in nearly every tissue type, attaches a phosphate group to NR, producing NMN. Skeletal muscle additionally expresses NRK2, which serves as a backup or muscle-specific route for the same reaction. The resulting NMN is then converted to NAD+ by the NMNAT family of enzymes, completing the salvage cycle.

This is the mechanistic key point: NR is the only oral precursor that uses the NRK gateway in humans. NMN, despite being one step closer to NAD+ on paper, cannot directly enter most cells without first being broken down to NR by ectoenzymes such as CD73, then re-phosphorylated by NRK1 inside the cell.

Brenner’s group, along with several independent labs, has produced evidence supporting this route. Imai and Guarente (2014) framed the broader NAD+ network in their key review, but the specific NMN-to-NR conversion question is one of the most actively debated in the field.

ChromaDex, Niagen, and why one company shaped the evidence base

Almost every published NR human trial uses Niagen, the patented crystalline NR chloride salt manufactured by ChromaDex. ChromaDex licensed Brenner’s foundational patents in 2012, partnered with academic centres across the United States, Europe, and Asia, and seeded what is now the largest body of clinical evidence for any NAD+ precursor.

By April 2026, ChromaDex’s public registry lists over thirty completed and ongoing human trials of Niagen NR, covering everything from basic pharmacokinetics to Parkinson’s disease and heart failure.

This commercial scaffolding cuts both ways. On the positive side, it means NR has been tested in real humans more thoroughly than any competitor, including NMN. On the cautious side, much of that evidence carries a financial relationship with the ingredient supplier, and as with any industry-funded literature, readers should look for independent replications.

The good news is that several have appeared. Airhart et al. (2017) ran an investigator-initiated open-label trial that confirmed the dose-response relationship Trammell first reported, and Lapatto et al. (2023) tested NR in identical twins discordant for body weight, again funded outside ChromaDex’s direct sponsorship.

What Trammell 2016 actually measured

The single most cited NR paper is Trammell et al. (2016), published in Nature Communications. It was the first careful pharmacokinetic study of oral NR in humans.

The design was straightforward: twelve healthy adults took single oral doses of 100 mg, 300 mg, and 1000 mg of Niagen NR in a crossover fashion, and the researchers measured the entire NAD+ metabolome in blood over 24 hours. Three findings shaped everything that came after.

First, NR raised whole-blood NAD+ in a clear dose-response pattern, peaking at roughly 8 hours. Second, the rise was sustained - blood NAD+ remained elevated above baseline for at least 24 hours after a single dose, suggesting once-daily dosing is biologically plausible. Third, no serious adverse events occurred at any dose.

These three results - that NR raises NAD+, does so persistently, and does so safely - are the bedrock on which the entire NR commercial category was built. Subsequent trials by Conze and colleagues (2019), Martens et al., and Lapatto’s twin study extended the dosing window from a single dose to weeks and months of daily intake, with the same reassuring profile.

Sirtuins, mitochondria, and what NR is really meant to do

Raising NAD+ is not the goal in itself. The goal is to restore the activity of NAD+-dependent enzymes that decline with age, especially the sirtuin family and the mitochondrial machinery that depends on NAD+ for oxidative phosphorylation.

Verdin (2015) reviewed how falling NAD+ correlates with sirtuin dysfunction in aged tissues, and how restoring NAD+ in mice tends to recover several markers of mitochondrial efficiency.

In NR-specific human work, the readouts so far have been intermediate. Lapatto’s twin study saw improvements in plasma lipid markers and shifts in adipose tissue gene expression that aligned with sirtuin activation. Other trials have measured small improvements in vascular function, blood pressure, and muscle protein turnover. None of these is a hard clinical endpoint - nobody has yet shown NR cuts heart attacks, dementia rates, or all-cause mortality.

Yoshino, Baur and Imai (2018), and Rajman et al. (2018), both stressed that the field is still early, and that biomarker improvement is not the same as clinical benefit. That caveat applies to NR as fully as it applies to NMN.

Regulatory standing in 2026: NR’s quiet advantage

One of the underappreciated reasons NR has held its ground commercially is regulatory. ChromaDex secured a New Dietary Ingredient notification with the United States Food and Drug Administration in 2016 and obtained Generally Recognized as Safe (GRAS) status soon after. This means in the world’s largest supplement market, NR is sold cleanly as a dietary ingredient.

NMN, by contrast, was effectively pushed out of the US dietary supplement category in 2022 when the FDA ruled that NMN had been studied as a drug before it appeared in food, disqualifying it under the dietary supplement definition.

For Malaysian consumers buying online or via grey-market channels, that ruling has knock-on effects. US-based brands with reliable third-party testing have largely stayed with NR. NMN is more often imported from China or Japan.

In Malaysia itself, both NR and NMN can be sold under National Pharmaceutical Regulatory Agency (NPRA) registration as supplements, provided the product carries a valid registration (MAL) number - verifiable via NPRAPRODUCT search. Halal certification is a separate gate handled by JAKIM, and several NR brands now carry recognised halal status, with bovine gelatin and pork-derived excipients as the main pitfalls to watch for.

Where the science is still genuinely unsettled

Three honest open questions remain, and any reader should know them before spending RM 200 a month on an NR jar. First, does NR raise NAD+ inside specific tissues that matter, such as the brain or heart, or only in blood and easy-to-sample tissues like muscle? Mass spectrometry data from animal studies and a handful of human muscle biopsy papers suggest yes, but coverage is thin.

Second, does long-term NR change clinical outcomes? Until a multi-year trial with mortality or cardiovascular endpoints is published, the answer remains: probably yes for biomarkers, possibly yes for function, unproven for hard outcomes.

Third, is NR truly distinct from NMN in living humans, or do both converge to the same intracellular pool of NAD+? Bi et al. (2023) and Yaku et al. (2025) review this convergence in detail, and the honest summary is that for the average healthy adult, the choice between NR and NMN is closer to a brand and price decision than a biological one.

Where the differences may matter - muscle dosing, neurological indications, fasted versus fed states - is exactly where future research is concentrating. The science is moving, the bottle on your shelf this week reflects 2024 evidence, and the frame is likely to look different by 2028.

How Malaysian buyers should read NR evidence

The useful way to read NR evidence is to separate three claims. The first claim is biochemical: oral NR raises NAD+ related markers in humans. That claim is well supported by pharmacokinetic work and repeated short trials.

The second claim is functional: raising NAD+ may improve markers such as vascular function, muscle metabolism, fatigue, or lipid handling in selected groups. That claim is plausible but more mixed. The third claim is the consumer claim that NR will slow aging in a visible, reliable way. That claim is not proven.

For a Malaysian buyer, this hierarchy matters because the label usually compresses all three claims into one promise. A bottle may say NAD+ support, healthy aging, cellular energy, and vitality in the same paragraph. Those phrases do not carry the same evidence weight. NAD+ support is the strongest. Cellular energy is a reasonable mechanism statement. Longevity benefit is still a research question.

When comparing NR with NMN, use the NR dosage guide, NR vs NMN deep dive, and NR safety guide as separate checks rather than treating one article as a verdict.

NR also has a different commercial footprint from NMN in Malaysia. Many NR products are built around the Niagen ingredient, which makes the chain of evidence easier to follow from ingredient to finished bottle. NMN products are more fragmented: some use Japanese raw material, some use Chinese raw material, and some only state a percentage purity without naming the supplier.

This does not make NR automatically better, but it does make documentation easier to audit. If a seller cannot name the ingredient form, capsule material, storage advice, and batch COA, the science behind NR does not rescue that specific product.

The final reading rule is to match the evidence to your reason for buying. If the goal is basic NAD+ precursor support and you can afford the premium, NR is one of the tidier choices. If the goal is a dramatic energy change within days, the published evidence does not justify that expectation.

If the goal is safer experimentation in an older adult taking several medications, the bigger question is not NR versus NMN but whether your doctor can review the stack, current medicines, liver and kidney history, and planned blood tests before you spend the money.

What to check on an NR label

An NR label should answer five questions without requiring a sales chat. First, what chemical form is used: nicotinamide riboside chloride, Niagen, or another named NR salt? Second, how many milligrams of actual NR are in each capsule, not only how much branded blend?

Third, who is responsible in Malaysia if the product is sold locally: importer, distributor, registration holder, or only an overseas marketplace seller? Fourth, what is the capsule shell: HPMC, gelatin, pullulan, or something unstated? Fifth, does the seller provide a batch COA that matches the lot number on the bottle?

Those checks turn the biology into buyer protection. A page about NRK enzymes explains why NR can raise NAD+; it does not prove the bottle in front of you is stable, legal, halal-suitable, or accurately dosed. Serious authority content in Malaysia has to connect mechanism to procurement.

The most useful reader journey is: understand how NR works, choose a conservative dose in the NR dosage guide, check risk groups in the NR safety guide, then compare products only after the label passes these basic screens.

The label should also avoid disease language. If an NR product says it treats diabetes, prevents dementia, repairs heart disease, or cures fatigue, that is not a stronger product; it is a weaker compliance signal.

The better labels use cautious structure-function language and point to ingredient evidence, not miracle outcomes. In Malaysia, that restraint matters because supplement advertising is watched by MOH rules as well as by consumers who need realistic expectations.